FDA unconvinced by J&J's Xarelto for heart attack patients

The FDA expresses skepticism that Johnson & Johnson's (JNJ) anticoagulant Xarelto (rivaroxaban) is effective in cutting the risk of additional heart problems in heart-attack patients.

J&J has recommended that Xarelto, which is already authorized for other uses, be administered in the 90 days after an attack.

However, the FDA doesn't see the point. "Not only does the effect of rivaroxaban not appear to be greater earlier, but an effect in the first 90 days or so is not apparent at all," the agency says in a review.

The FDA's comments come two days before an advisory panel is due to discuss whether to recommend Xarelto for this indication.

Bayer (BAYRY) co-markets Xarelto.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs